Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
7857 | 1242 | 28.9 | 83% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
126 | 23061 | TRANSPLANTATION//TRANSPLANTATION PROCEEDINGS//MYCOPHENOLIC ACID |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SUBCLINICAL REJECTION | Author keyword | 36 | 69% | 2% | 31 |
2 | PROTOCOL BIOPSY | Author keyword | 21 | 44% | 3% | 37 |
3 | ALBERTA TRANSPLANT PL GENOM | Address | 17 | 54% | 2% | 22 |
4 | PROTOCOL BIOPSIES | Author keyword | 17 | 50% | 2% | 24 |
5 | CHRONIC ALLOGRAFT NEPHROPATHY | Author keyword | 14 | 20% | 5% | 63 |
6 | BANFF CLASSIFICATION | Author keyword | 10 | 46% | 1% | 17 |
7 | INTIMAL ARTERITIS | Author keyword | 9 | 83% | 0% | 5 |
8 | TUBULITIS | Author keyword | 7 | 43% | 1% | 13 |
9 | TRANSPLANTAT MED EXTRACORPOREAL THER Y | Address | 6 | 71% | 0% | 5 |
10 | NEPHROL TRANSPLANTAT IMMUNOL | Address | 4 | 32% | 1% | 11 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SUBCLINICAL REJECTION | 36 | 69% | 2% | 31 | Search SUBCLINICAL+REJECTION | Search SUBCLINICAL+REJECTION |
2 | PROTOCOL BIOPSY | 21 | 44% | 3% | 37 | Search PROTOCOL+BIOPSY | Search PROTOCOL+BIOPSY |
3 | PROTOCOL BIOPSIES | 17 | 50% | 2% | 24 | Search PROTOCOL+BIOPSIES | Search PROTOCOL+BIOPSIES |
4 | CHRONIC ALLOGRAFT NEPHROPATHY | 14 | 20% | 5% | 63 | Search CHRONIC+ALLOGRAFT+NEPHROPATHY | Search CHRONIC+ALLOGRAFT+NEPHROPATHY |
5 | BANFF CLASSIFICATION | 10 | 46% | 1% | 17 | Search BANFF+CLASSIFICATION | Search BANFF+CLASSIFICATION |
6 | INTIMAL ARTERITIS | 9 | 83% | 0% | 5 | Search INTIMAL+ARTERITIS | Search INTIMAL+ARTERITIS |
7 | TUBULITIS | 7 | 43% | 1% | 13 | Search TUBULITIS | Search TUBULITIS |
8 | PATHOLOGY OF RENAL TRANSPLANTATION | 4 | 75% | 0% | 3 | Search PATHOLOGY+OF+RENAL+TRANSPLANTATION | Search PATHOLOGY+OF+RENAL+TRANSPLANTATION |
9 | BANFF | 4 | 36% | 1% | 9 | Search BANFF | Search BANFF |
10 | CHRONIC ALLOGRAFT INJURY | 4 | 36% | 1% | 9 | Search CHRONIC+ALLOGRAFT+INJURY | Search CHRONIC+ALLOGRAFT+INJURY |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SUBCLINICAL REJECTION | 71 | 58% | 7% | 82 |
2 | PROTOCOL BIOPSIES | 58 | 41% | 9% | 111 |
3 | BANFF CLASSIFICATION | 53 | 95% | 1% | 18 |
4 | WORKING CLASSIFICATION | 40 | 43% | 6% | 72 |
5 | HUMAN KIDNEY TRANSPLANTS | 21 | 78% | 1% | 14 |
6 | CHRONIC ALLOGRAFT NEPHROPATHY | 16 | 16% | 8% | 95 |
7 | SURVEILLANCE BIOPSIES | 12 | 86% | 0% | 6 |
8 | BASE LINE IMMUNOSUPPRESSION | 11 | 100% | 0% | 6 |
9 | HISTOPATHOLOGICAL FINDINGS | 11 | 28% | 3% | 32 |
10 | CTL ASSOCIATED TRANSCRIPTS | 11 | 78% | 1% | 7 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
The significance of histological diagnosis in renal allograft biopsies in 2014 | 2015 | 2 | 81 | 40% |
Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies | 2014 | 13 | 44 | 32% |
The significance of subclinical rejection and the value of protocol biopsies | 2006 | 64 | 32 | 78% |
The Banff classification revisited | 2013 | 15 | 23 | 70% |
Urinary cell mRNA profiles predictive of human kidney allograft status | 2014 | 7 | 36 | 47% |
Noninvasive prediction of organ graft rejection and outcome using gene expression patterns | 2008 | 33 | 50 | 62% |
Noninvasive diagnosis of acute rejection of renal allografts | 2010 | 31 | 48 | 52% |
Biomarkers and surrogate endpoints in renal transplantation: Present status and considerations for clinical trial design | 2004 | 42 | 28 | 79% |
Protocol biopsies in renal transplantation: Prognostic value of structural monitoring | 2007 | 34 | 58 | 67% |
Surveillance Protocol Kidney Transplant Biopsies: Their Evolving Role in Clinical Practice | 2011 | 22 | 50 | 50% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ALBERTA TRANSPLANT PL GENOM | 17 | 54% | 1.8% | 22 |
2 | TRANSPLANTAT MED EXTRACORPOREAL THER Y | 6 | 71% | 0.4% | 5 |
3 | NEPHROL TRANSPLANTAT IMMUNOL | 4 | 32% | 0.9% | 11 |
4 | PEDIAT CHILD HLTH NEPHROL | 2 | 67% | 0.2% | 2 |
5 | TRANSPLANT IMMUNOBIOL GRP | 2 | 50% | 0.2% | 3 |
6 | NEPHROL TRANSPLANT IMMUNOL | 2 | 20% | 0.7% | 9 |
7 | LIVER IMMUNOBIOL | 1 | 38% | 0.2% | 3 |
8 | HOSP CHILDREN ADOLESCENTS PEDIAT NEPHROL TRAN | 1 | 100% | 0.2% | 2 |
9 | MOL TRANSPLANT | 1 | 50% | 0.2% | 2 |
10 | PROOF EXCELLENCE | 1 | 100% | 0.2% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000184842 | DERRIFORD COMBINED S//CYTOKINE GENE POLYMORPHISM//CLINICIZZATA CHIRURG 2 |
2 | 0.0000178528 | POSTTRANSPLANTATION HYPERTENSION//POST TRANSPLANT NEPHROTIC SYNDROME//POST TRANSPLANT HYPERTENSION |
3 | 0.0000151934 | ANTIBODY MEDIATED REJECTION//C4D//HLA ANTIBODIES |
4 | 0.0000142984 | DELAYED GRAFT FUNCTION//EXPANDED CRITERIA DONORS//EXPANDED CRITERIA DONOR |
5 | 0.0000127284 | SIROLIMUS//EVEROLIMUS//PROLIFERATION SIGNAL INHIBITORS |
6 | 0.0000121950 | STEROID WITHDRAWAL//CORTICOSTEROID WITHDRAWAL//EARLY STEROID WITHDRAWAL |
7 | 0.0000106942 | RECURRENT GLOMERULONEPHRITIS//RECURRENT IGA NEPHROPATHY//DE NOVO GLOMERULONEPHRITIS |
8 | 0.0000092501 | PERCUTANEOUS RENAL BIOPSY//RENAL BIOPSY//TRANSJUGULAR RENAL BIOPSY |
9 | 0.0000091835 | NEW STERNHEIMER STAINING//GRAFT INFILTRATING CELLS//EX VIVO PROPAGATION |
10 | 0.0000089692 | BASILIXIMAB//THYMOGLOBULIN//DACLIZUMAB |